Prostate Cancer:@0.762090:0.035749:0.914561:0.035749:0.914561:0.019993:0.762090:0.019993:0.011392:0.005709:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.005330:0.015644:0.013143:0.011738:0.012450:0.012508:0.005792
TREATMENT APPROACHES:@0.983689:0.278245:0.983689:0.065272:0.955679:0.065272:0.955679:0.278245:0.000000:0.000000:0.000000:0.057096:-0.123230:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.375913
65:@0.955522:0.038184:0.976595:0.038184:0.976595:0.018587:0.955522:0.018587:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
and higher where only EBRT is used. :@0.104091:0.096166:0.437823:0.096166:0.437823:0.080410:0.104091:0.080410:0.013143:0.011738:0.013181:0.005330:0.011738:0.003848:0.012950:0.011738:0.012508:0.005792:0.005330:0.015990:0.011738:0.012508:0.005694:0.012508:0.005330:0.012604:0.011738:0.003848:0.010314:0.005330:0.010314:0.011045:0.011790:0.008197:0.005330:0.003848:0.007466:0.005330:0.011699:0.007466:0.012508:0.013181:0.005330:0.005330
It can be argued that this will lead to :@0.104091:0.112583:0.452013:0.112583:0.452013:0.096827:0.104091:0.096827:0.004349:0.006523:0.005330:0.012450:0.013143:0.011738:0.005330:0.013123:0.012508:0.005330:0.013143:0.005792:0.012950:0.011699:0.012508:0.013181:0.005330:0.006523:0.011738:0.013143:0.006523:0.005330:0.006523:0.011738:0.003848:0.007466:0.005330:0.015990:0.003848:0.003848:0.003848:0.005330:0.003848:0.012508:0.013143:0.013181:0.005330:0.006523:0.012604:0.005330
underdosing of para-prostatic spread :@0.104091:0.129000:0.458751:0.129000:0.458751:0.113244:0.104091:0.113244:0.011699:0.011738:0.013181:0.012508:0.005671:0.013181:0.012604:0.007466:0.003848:0.011738:0.012950:0.005330:0.012604:0.006042:0.005330:0.013123:0.013143:0.005792:0.013143:0.006388:0.013123:0.005705:0.012604:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330:0.007466:0.013123:0.005715:0.012508:0.013143:0.013181:0.005330
of the cancer.:@0.104091:0.145418:0.236140:0.145418:0.236140:0.129662:0.104091:0.129662:0.012604:0.006042:0.005330:0.006523:0.011738:0.012508:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.004356:0.005330
Disadvantages  of brachytherapy: This is :@0.084848:0.178253:0.481086:0.178253:0.481086:0.162497:0.084848:0.162497:0.014316:0.003848:0.007466:0.013143:0.013181:0.010660:0.013143:0.011738:0.006523:0.013143:0.012950:0.012508:0.007466:0.005330:0.005829:0.012604:0.006042:0.011141:0.013123:0.005792:0.013143:0.012450:0.011738:0.010314:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.011141:0.008197:0.011738:0.003848:0.007466:0.011141:0.003848:0.007466:0.005330
an invasive technique,  causing  a risk of :@0.084848:0.194670:0.481103:0.194670:0.481103:0.178914:0.084848:0.178914:0.013143:0.011738:0.009814:0.003848:0.011738:0.010660:0.013143:0.007466:0.003848:0.010660:0.012508:0.009814:0.006523:0.012508:0.012450:0.011738:0.011738:0.003848:0.013123:0.011699:0.012508:0.005330:0.005330:0.004470:0.012450:0.013143:0.011699:0.007466:0.003848:0.011738:0.012950:0.005330:0.004474:0.013143:0.009814:0.005792:0.003848:0.007466:0.009660:0.009814:0.012604:0.006042:0.005330
infections and bleeding, impotence, stric-:@0.084848:0.211087:0.475767:0.211087:0.475767:0.195331:0.084848:0.195331:0.003848:0.011738:0.006042:0.012508:0.012450:0.006523:0.003848:0.012604:0.011738:0.007466:0.005975:0.013143:0.011738:0.013181:0.005984:0.013123:0.003848:0.012508:0.012508:0.013181:0.003848:0.011738:0.012950:0.005330:0.005984:0.003848:0.018049:0.013123:0.012604:0.006523:0.012508:0.011738:0.012450:0.012508:0.005330:0.005965:0.007466:0.006523:0.005792:0.003848:0.012450:0.006388
tures of the urethra treated with dilatations :@0.084848:0.227505:0.481101:0.227505:0.481101:0.211749:0.084848:0.211749:0.006523:0.011699:0.005707:0.012508:0.007466:0.004407:0.012604:0.006042:0.004407:0.006523:0.011738:0.012508:0.004397:0.011699:0.005711:0.012508:0.006523:0.011738:0.005792:0.013143:0.004407:0.006523:0.005711:0.012508:0.013143:0.006523:0.012508:0.013181:0.004407:0.015990:0.003848:0.006523:0.011738:0.004407:0.013181:0.003848:0.003848:0.013143:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330
and gastro-intestinal morbidity – e.g., rec-:@0.084848:0.243922:0.475754:0.243922:0.475754:0.228166:0.084848:0.228166:0.013143:0.011738:0.013181:0.006292:0.012950:0.013143:0.007466:0.006523:0.005713:0.012604:0.006388:0.003848:0.011738:0.006523:0.012508:0.007466:0.006523:0.003848:0.011738:0.013143:0.003848:0.006304:0.018049:0.012604:0.005792:0.013123:0.003848:0.013181:0.003848:0.006523:0.010314:0.006292:0.009621:0.006292:0.012508:0.005330:0.012950:0.005330:0.005330:0.006283:0.005711:0.012508:0.012450:0.006388
tal bleeding, rectal ulcer or prostatorectal :@0.084848:0.260340:0.481092:0.260340:0.481092:0.244584:0.084848:0.244584:0.006523:0.013143:0.003848:0.005523:0.013123:0.003848:0.012508:0.012508:0.013181:0.003848:0.011738:0.012950:0.005330:0.005523:0.005711:0.012508:0.012450:0.006523:0.013143:0.003848:0.005523:0.011699:0.003848:0.012450:0.012508:0.005792:0.005523:0.012604:0.005792:0.005523:0.013123:0.005715:0.012604:0.007466:0.006523:0.013143:0.006523:0.012604:0.005703:0.012508:0.012450:0.006523:0.013143:0.003848:0.005330
fistulae (rare).:@0.084848:0.276757:0.211419:0.276757:0.211419:0.261001:0.084848:0.261001:0.004686:0.004686:0.007466:0.006523:0.011699:0.003848:0.013143:0.012508:0.005330:0.007100:0.005792:0.013143:0.005709:0.012508:0.007100:0.005330
HORMONAL MANAGEMENT:@0.084848:0.309877:0.364932:0.309877:0.364932:0.292062:0.084848:0.292062:0.014539:0.017960:0.012401:0.019242:0.017960:0.015822:0.015822:0.009407:0.005987:0.019242:0.015822:0.015822:0.015822:0.017960:0.011118:0.019242:0.011118:0.015822:0.008980
Hormone treatment includes androgen :@0.084848:0.327438:0.481130:0.327438:0.481130:0.311682:0.084848:0.311682:0.012950:0.012411:0.006131:0.017857:0.012411:0.011545:0.012315:0.015471:0.006331:0.005519:0.012315:0.012950:0.006331:0.017857:0.012315:0.011545:0.006331:0.015471:0.003656:0.011545:0.012257:0.003656:0.011507:0.012989:0.012315:0.007274:0.015471:0.012950:0.011545:0.012989:0.005521:0.012411:0.012758:0.012315:0.011736:0.005330
deprivation therapy (ADT) which results :@0.084848:0.343856:0.481105:0.343856:0.481105:0.328100:0.084848:0.328100:0.012989:0.012315:0.012931:0.005600:0.003656:0.010468:0.012950:0.006331:0.003656:0.012411:0.011545:0.013855:0.006331:0.011545:0.012315:0.005600:0.012950:0.012931:0.010122:0.013855:0.006908:0.014047:0.014124:0.008005:0.006908:0.013855:0.015798:0.011545:0.003656:0.012257:0.011545:0.013855:0.005519:0.012315:0.007274:0.011507:0.003656:0.006331:0.007468:0.005330
in medical castration and anti-androgen :@0.084848:0.360273:0.481082:0.360273:0.481082:0.344517:0.084848:0.344517:0.003656:0.011545:0.009583:0.017857:0.012315:0.012989:0.003656:0.012257:0.012950:0.003656:0.009583:0.012257:0.012950:0.007274:0.006331:0.005600:0.012950:0.006331:0.003656:0.012411:0.011545:0.009583:0.012950:0.011545:0.012989:0.009583:0.012950:0.011545:0.006331:0.003656:0.006196:0.012950:0.011545:0.012989:0.005521:0.012411:0.012758:0.012315:0.011734:0.005330
therapy. Anti-androgen drugs are classified :@0.084848:0.376690:0.481101:0.376690:0.481101:0.360934:0.084848:0.360934:0.006331:0.011545:0.012315:0.005600:0.012950:0.012931:0.010122:0.005138:0.004381:0.014047:0.011545:0.006331:0.003656:0.006196:0.012950:0.011545:0.012989:0.005521:0.012411:0.012758:0.012315:0.011545:0.004381:0.012989:0.005600:0.011507:0.012758:0.007274:0.004381:0.012950:0.005521:0.012315:0.004383:0.012257:0.003656:0.012950:0.007274:0.007274:0.003656:0.004589:0.004589:0.012315:0.013181:0.005330
as first- and second-line receptor blockers :@0.084848:0.393108:0.481105:0.393108:0.481105:0.377352:0.084848:0.377352:0.012950:0.007274:0.007339:0.004589:0.004589:0.005600:0.007274:0.006331:0.006196:0.007339:0.012950:0.011545:0.012989:0.007339:0.007274:0.012315:0.012257:0.012411:0.011545:0.012989:0.006196:0.003656:0.003656:0.011545:0.012315:0.007337:0.005521:0.012315:0.012257:0.012315:0.012931:0.006331:0.012411:0.005600:0.007339:0.012931:0.003656:0.012411:0.012257:0.009467:0.012315:0.005600:0.007468:0.005330
(such as bicalutamide, enzalutamide cy-:@0.084848:0.409525:0.475758:0.409525:0.475758:0.393769:0.084848:0.393769:0.006908:0.007274:0.011507:0.012257:0.011545:0.009544:0.012950:0.007274:0.009544:0.012931:0.003656:0.012257:0.012950:0.003656:0.011507:0.006331:0.012950:0.017857:0.003656:0.012989:0.012315:0.005138:0.009544:0.012315:0.011545:0.007986:0.012950:0.003656:0.011507:0.006331:0.012950:0.017857:0.003656:0.012989:0.012315:0.009544:0.012257:0.010122:0.006388
proterone acetate) or an androgen syn-:@0.084848:0.425943:0.475810:0.425943:0.475810:0.410187:0.084848:0.410187:0.012931:0.005521:0.012411:0.006331:0.012315:0.005521:0.012411:0.011545:0.012315:0.009487:0.012950:0.012257:0.012315:0.006331:0.012950:0.006331:0.012315:0.006908:0.009487:0.012411:0.005600:0.009487:0.012950:0.011545:0.009487:0.012950:0.011545:0.012989:0.005521:0.012411:0.012758:0.012315:0.011545:0.009487:0.007274:0.010122:0.011545:0.006388
thesis inhibitor (abiraterone acetate).:@0.084848:0.442360:0.423107:0.442360:0.423107:0.426604:0.084848:0.426604:0.006331:0.011545:0.012315:0.007274:0.003656:0.007274:0.005138:0.003656:0.011545:0.011545:0.003656:0.012931:0.003656:0.006331:0.012411:0.005600:0.005138:0.006908:0.012950:0.012931:0.003656:0.005600:0.012950:0.006331:0.012315:0.005519:0.012411:0.011545:0.012315:0.005138:0.012950:0.012257:0.012315:0.006331:0.012950:0.006331:0.012315:0.006908:0.005330
Eligible  patients are from intermediate :@0.103032:0.458777:0.481105:0.458777:0.481105:0.443021:0.103032:0.443021:0.010314:0.003848:0.003848:0.012950:0.003848:0.013123:0.003848:0.012508:0.005330:0.004457:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.009775:0.013143:0.005715:0.012508:0.009775:0.006042:0.005711:0.012604:0.018049:0.009775:0.003848:0.011738:0.006523:0.012508:0.006321:0.018049:0.012508:0.013181:0.003848:0.013143:0.006523:0.012508:0.005330
risk-,  high-  and  very  high-risk  groups,  as :@0.084848:0.475195:0.481086:0.475195:0.481086:0.459439:0.084848:0.459439:0.005792:0.003848:0.007466:0.009660:0.006388:0.005330:0.005330:0.005588:0.011738:0.003848:0.012950:0.011738:0.006388:0.005330:0.005586:0.013143:0.011738:0.013181:0.005330:0.005588:0.010660:0.012508:0.005792:0.010314:0.005330:0.005588:0.011738:0.003848:0.012950:0.011738:0.006388:0.005792:0.003848:0.007466:0.009660:0.005330:0.005588:0.012950:0.005709:0.012604:0.011699:0.013123:0.007466:0.005330:0.005330:0.005586:0.013143:0.007466:0.005330
well as those with metastatic disease.:@0.084848:0.491612:0.432866:0.491612:0.432866:0.475856:0.084848:0.475856:0.015990:0.012508:0.003848:0.003848:0.005330:0.013143:0.007466:0.005330:0.006523:0.011738:0.012604:0.007466:0.012508:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330
Androgen-deprivation therapy:@0.084848:0.524735:0.402134:0.524735:0.402134:0.506714:0.084848:0.506714:0.015822:0.012828:0.014111:0.006842:0.013683:0.014111:0.013683:0.012828:0.008980:0.014111:0.013683:0.014111:0.006842:0.005131:0.011973:0.014111:0.006414:0.005131:0.013683:0.012828:0.005987:0.006414:0.012828:0.013683:0.006842:0.014111:0.014111:0.012401
Sustained-release luteinising hormone-:@0.084848:0.542296:0.475764:0.542296:0.475764:0.526540:0.084848:0.526540:0.009583:0.011699:0.007466:0.006523:0.013143:0.003848:0.011738:0.012508:0.013181:0.006388:0.005715:0.012508:0.003848:0.012508:0.013143:0.007466:0.012508:0.022591:0.003848:0.011699:0.006523:0.012508:0.003848:0.011738:0.003848:0.007466:0.003848:0.011738:0.012950:0.022591:0.011738:0.012604:0.006317:0.018049:0.012604:0.011738:0.012508:0.006388
releasing hormone  (LHRH) agonists and :@0.084848:0.558714:0.481094:0.558714:0.481094:0.542958:0.084848:0.542958:0.005713:0.012508:0.003848:0.012508:0.013143:0.007466:0.003848:0.011738:0.012950:0.011699:0.011738:0.012604:0.006315:0.018049:0.012604:0.011738:0.012508:0.005330:0.006354:0.007100:0.008890:0.013143:0.011680:0.013143:0.007100:0.011699:0.013143:0.012950:0.012604:0.011738:0.003848:0.007466:0.006523:0.007466:0.011699:0.013143:0.011738:0.013181:0.005330
antagonists are available  in one-month, :@0.084848:0.575131:0.481111:0.575131:0.481111:0.559375:0.084848:0.559375:0.013143:0.011738:0.006523:0.013143:0.012950:0.012604:0.011738:0.003848:0.007466:0.006523:0.007466:0.010083:0.013143:0.005715:0.012508:0.010083:0.013143:0.010660:0.013143:0.003848:0.003848:0.013143:0.013123:0.003848:0.012508:0.005330:0.004776:0.003848:0.011738:0.010083:0.012604:0.011738:0.012508:0.006388:0.018049:0.012604:0.011738:0.006523:0.011738:0.005330:0.005330
three-month  and  six-month  formulations. :@0.084848:0.591548:0.481086:0.591548:0.481086:0.575793:0.084848:0.575793:0.006523:0.011738:0.005707:0.012508:0.012508:0.006388:0.018049:0.012604:0.011738:0.006523:0.011738:0.005330:0.004668:0.013143:0.011738:0.013181:0.005330:0.004680:0.007466:0.003848:0.009236:0.006388:0.018049:0.012604:0.011738:0.006523:0.011738:0.005330:0.004678:0.006042:0.012604:0.006319:0.018049:0.011699:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.005330
Phase  II  data indicate equivalence  be-:@0.084848:0.607966:0.475762:0.607966:0.475762:0.592210:0.084848:0.592210:0.011392:0.011738:0.013143:0.007466:0.012508:0.005330:0.005201:0.004349:0.004349:0.005330:0.005205:0.013181:0.013143:0.006523:0.013143:0.010545:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.010545:0.012508:0.013123:0.011699:0.003848:0.010660:0.013143:0.003848:0.012508:0.011738:0.012450:0.012508:0.005330:0.005203:0.013123:0.012508:0.006388
tween agonists and antagonists. Antago-:@0.084848:0.624383:0.475758:0.624383:0.475758:0.608627:0.084848:0.608627:0.006523:0.015990:0.012508:0.012508:0.011738:0.006945:0.013143:0.012950:0.012604:0.011738:0.003848:0.007466:0.006523:0.007466:0.006952:0.013143:0.011738:0.013181:0.006952:0.013143:0.011738:0.006523:0.013143:0.012950:0.012604:0.011728:0.003848:0.007466:0.006523:0.007466:0.005330:0.006966:0.014239:0.011738:0.006523:0.013143:0.012950:0.012585:0.006388
nists (Degarelix) do not result in the flare-up :@0.084848:0.640801:0.481086:0.640801:0.481086:0.625045:0.084848:0.625045:0.011738:0.003848:0.007466:0.006523:0.007466:0.004139:0.007100:0.014316:0.012508:0.012950:0.013143:0.005715:0.012508:0.003848:0.003848:0.009236:0.007100:0.004141:0.013181:0.012604:0.004129:0.011738:0.012604:0.006523:0.004124:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.004133:0.003848:0.011738:0.004131:0.006523:0.011738:0.012508:0.004126:0.004666:0.004666:0.013143:0.005713:0.012508:0.006388:0.011699:0.013123:0.005330
of symptoms and are therefore indicated :@0.084848:0.657218:0.481098:0.657218:0.481098:0.641462:0.084848:0.641462:0.012604:0.006042:0.006591:0.007466:0.010314:0.018049:0.013123:0.006523:0.012604:0.018049:0.007466:0.006600:0.013143:0.011738:0.013181:0.006600:0.013143:0.005715:0.012508:0.006600:0.006523:0.011738:0.012508:0.005703:0.012508:0.006042:0.012604:0.005707:0.012508:0.006600:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.005330
in cord compression and cases of severe :@0.084848:0.673635:0.481059:0.673635:0.481059:0.657880:0.084848:0.657880:0.003848:0.011738:0.007120:0.012450:0.012604:0.005669:0.013181:0.007120:0.012450:0.012604:0.018049:0.013123:0.005711:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.007120:0.013143:0.011738:0.013181:0.007120:0.012450:0.013143:0.007466:0.012508:0.007466:0.007120:0.012604:0.006042:0.007120:0.007466:0.012508:0.010660:0.012508:0.005717:0.012508:0.005330
outflow obstruction.:@0.084848:0.690053:0.268633:0.690053:0.268633:0.674297:0.084848:0.674297:0.012604:0.011699:0.006523:0.004666:0.004666:0.012604:0.015990:0.005330:0.012604:0.013123:0.007466:0.006523:0.005792:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330
Androgen-deprivation therapy (ADT) is used::@0.084848:0.722888:0.475542:0.722888:0.475542:0.707132:0.084848:0.707132:0.013662:0.011161:0.012604:0.005134:0.012027:0.012373:0.011930:0.011161:0.005811:0.012604:0.011930:0.012546:0.005215:0.003271:0.010083:0.012565:0.005946:0.003271:0.012027:0.011161:0.004753:0.005946:0.011161:0.011930:0.005215:0.012565:0.012546:0.009737:0.004753:0.006523:0.013662:0.013739:0.007620:0.006523:0.004753:0.003271:0.006889:0.004753:0.011122:0.006889:0.011930:0.012604:0.005330
n   :@0.084848:0.736151:0.107657:0.736151:0.107657:0.727711:0.084848:0.727711:0.009762:0.003566:0.005914:0.003566
In combination with radiotherapy for a :@0.104091:0.739270:0.469215:0.739270:0.469215:0.723514:0.104091:0.723514:0.004349:0.011738:0.005330:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.005792:0.013143:0.013181:0.003848:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.006042:0.012604:0.005792:0.005330:0.013143:0.005330
limited time period, depending on the :@0.104091:0.755687:0.465078:0.755687:0.465078:0.739932:0.104091:0.739932:0.003848:0.003848:0.018049:0.003848:0.006523:0.012508:0.013181:0.005330:0.006523:0.003848:0.018049:0.012508:0.005330:0.013123:0.012508:0.005792:0.003848:0.012604:0.013181:0.005330:0.005330:0.013181:0.012508:0.013123:0.012508:0.011738:0.013181:0.003848:0.011738:0.012950:0.005330:0.012604:0.011738:0.005330:0.006523:0.011738:0.012508:0.005330
risk group. This has shown to increase :@0.104091:0.772105:0.451187:0.772105:0.451187:0.756349:0.104091:0.756349:0.005792:0.003848:0.007466:0.009660:0.005330:0.012950:0.005709:0.012604:0.011699:0.013123:0.005330:0.005330:0.008197:0.011738:0.003848:0.007466:0.005330:0.011738:0.013143:0.007466:0.005330:0.007466:0.011738:0.012604:0.015990:0.011738:0.005330:0.006523:0.012604:0.005330:0.003848:0.011738:0.012450:0.005684:0.012508:0.013143:0.007466:0.012508:0.005330
the radiation effectiveness with better :@0.104091:0.788522:0.462713:0.788522:0.462713:0.772766:0.104091:0.772766:0.006523:0.011738:0.012508:0.005330:0.005792:0.013143:0.013181:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.012508:0.006083:0.006042:0.012508:0.012450:0.006523:0.003848:0.010660:0.012508:0.011738:0.012508:0.007466:0.007466:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.013123:0.012508:0.006523:0.006523:0.012508:0.005792:0.005330
outcomes:@0.104091:0.804940:0.197994:0.804940:0.197994:0.789184:0.104091:0.789184:0.012604:0.011699:0.006523:0.012450:0.012604:0.018049:0.012508:0.007466
n   :@0.084848:0.818223:0.107657:0.818223:0.107657:0.809783:0.084848:0.809783:0.009762:0.003566:0.005914:0.003566
In relapsed patients after radiotherapy :@0.104091:0.821342:0.468902:0.821342:0.468902:0.805587:0.104091:0.805587:0.004349:0.011738:0.005330:0.005709:0.012508:0.003848:0.013143:0.013123:0.007466:0.012508:0.013181:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.013143:0.006042:0.006523:0.012508:0.005792:0.005330:0.005792:0.013143:0.013181:0.003848:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
and/or surgery:@0.104091:0.837760:0.240808:0.837760:0.240808:0.822004:0.104091:0.822004:0.013143:0.011738:0.013181:0.008409:0.012604:0.005792:0.005330:0.007466:0.011699:0.005792:0.012950:0.012508:0.005792:0.010314
n   :@0.084848:0.851052:0.107657:0.851052:0.107657:0.842612:0.084848:0.842612:0.009762:0.003566:0.005914:0.003566
In metastatic disease:@0.104091:0.854171:0.301133:0.854171:0.301133:0.838415:0.104091:0.838415:0.004349:0.011738:0.005330:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508
n   :@0.084848:0.867467:0.107657:0.867467:0.107657:0.859026:0.084848:0.859026:0.009762:0.003566:0.005914:0.003566
As the only therapy in frail patients with :@0.104091:0.870586:0.472082:0.870586:0.472082:0.854830:0.104091:0.854830:0.014239:0.007466:0.005330:0.006523:0.011738:0.012508:0.005330:0.012604:0.011738:0.003848:0.010314:0.005330:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.003848:0.011738:0.005330:0.006042:0.005792:0.013143:0.003848:0.003848:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330
limited life expectancy.:@0.104091:0.887003:0.322126:0.887003:0.322126:0.871247:0.104091:0.871247:0.003848:0.003848:0.018049:0.003848:0.006523:0.012508:0.013181:0.005330:0.003848:0.003848:0.006042:0.012508:0.005330:0.012508:0.009236:0.013123:0.012508:0.012450:0.006523:0.013143:0.011738:0.012450:0.010314:0.005330
Intermittent:@0.084848:0.919838:0.191996:0.919838:0.191996:0.904082:0.084848:0.904082:0.004349:0.011738:0.006523:0.012508:0.006317:0.018049:0.003848:0.006523:0.006523:0.012508:0.011738:0.006523
 versus:@0.191996:0.919838:0.261769:0.919838:0.261769:0.904082:0.191996:0.904082:0.014182:0.010660:0.012508:0.005792:0.007466:0.011699:0.007466
 continuous ADT has :@0.261769:0.919838:0.481098:0.919838:0.481098:0.904082:0.261769:0.904082:0.014182:0.012450:0.012604:0.011738:0.006523:0.003848:0.011738:0.011699:0.012588:0.011699:0.007466:0.014182:0.014239:0.014316:0.008197:0.014182:0.011738:0.013143:0.007466:0.005330
been tested in large randomised studies, :@0.084848:0.936255:0.481107:0.936255:0.481107:0.920499:0.084848:0.920499:0.013123:0.012508:0.012508:0.011738:0.007793:0.006523:0.012508:0.007466:0.006523:0.012508:0.013181:0.007793:0.003848:0.011738:0.007793:0.003848:0.013143:0.005811:0.012950:0.012508:0.007793:0.005792:0.013143:0.011738:0.013181:0.012604:0.018049:0.003848:0.007466:0.012508:0.013181:0.007793:0.007466:0.006523:0.011699:0.013181:0.003848:0.012508:0.007466:0.005330:0.005330
with the latter showing a reduction in :@0.524249:0.096177:0.920504:0.096177:0.920504:0.080421:0.524249:0.080421:0.015990:0.003848:0.006523:0.011738:0.013066:0.006523:0.011738:0.012508:0.013066:0.003848:0.013143:0.006523:0.006523:0.012508:0.005792:0.013066:0.007466:0.011738:0.012604:0.015990:0.003848:0.011738:0.012950:0.013066:0.013143:0.013066:0.005711:0.012508:0.013181:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.013066:0.003848:0.011738:0.005330
prostate-cancer  mortality compared to :@0.524249:0.112647:0.920511:0.112647:0.920511:0.096891:0.524249:0.096891:0.013123:0.005715:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.006388:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.007429:0.018049:0.012604:0.005792:0.006523:0.013143:0.003848:0.003848:0.006523:0.010314:0.012777:0.012450:0.012604:0.018049:0.013123:0.013143:0.005717:0.012508:0.013181:0.012777:0.006523:0.012604:0.005330
the  intermittent regimen.  While ADT  has :@0.524249:0.129118:0.920504:0.129118:0.920504:0.113362:0.524249:0.113362:0.006523:0.011738:0.012508:0.005330:0.004934:0.003848:0.011738:0.006523:0.012508:0.006325:0.018049:0.003848:0.006523:0.006523:0.012508:0.011738:0.006523:0.010275:0.005713:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.005330:0.005330:0.004932:0.018473:0.011738:0.003848:0.003848:0.012508:0.010275:0.014239:0.014316:0.008197:0.005330:0.004936:0.011738:0.013143:0.007466:0.005330
a major role to play in improving results of :@0.524249:0.145588:0.920482:0.145588:0.920482:0.129832:0.524249:0.129832:0.013143:0.006004:0.018049:0.013143:0.003906:0.012604:0.005792:0.006004:0.005713:0.012604:0.003848:0.012508:0.006004:0.006523:0.012604:0.006004:0.013123:0.003848:0.013143:0.010314:0.006017:0.003848:0.011738:0.006004:0.003848:0.018049:0.013123:0.005719:0.012604:0.010660:0.003848:0.011738:0.012950:0.006004:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.007466:0.006004:0.012604:0.006042:0.005330
treatment  and managing  symptomatic :@0.524249:0.162058:0.920490:0.162058:0.920490:0.146302:0.524249:0.146302:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.007988:0.013143:0.011738:0.013181:0.013335:0.018049:0.013143:0.011738:0.013143:0.012950:0.003848:0.011738:0.012950:0.005330:0.007991:0.007466:0.010314:0.018049:0.013123:0.006523:0.012604:0.018049:0.013143:0.006523:0.003848:0.012450:0.005330
disease, patients who  rely on ADT  alone :@0.524249:0.178528:0.920515:0.178528:0.920515:0.162773:0.524249:0.162773:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.008832:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.008832:0.015990:0.011738:0.012604:0.005330:0.003487:0.005713:0.012508:0.003848:0.010314:0.008832:0.012604:0.011738:0.008832:0.014239:0.014316:0.008197:0.005330:0.003489:0.013143:0.003848:0.012604:0.011738:0.012508:0.005330
will ultimately relapse.:@0.524249:0.194999:0.726402:0.194999:0.726402:0.179243:0.524249:0.179243:0.015990:0.003848:0.003848:0.003848:0.005330:0.011699:0.003848:0.006523:0.003848:0.018049:0.013143:0.006523:0.012508:0.003848:0.010314:0.005330:0.005727:0.012508:0.003848:0.013143:0.013123:0.007466:0.012508:0.005330
4:@0.726400:0.189379:0.732615:0.189379:0.732615:0.180194:0.726400:0.180194:0.006215
Disadvantages of ADT include hot flush-:@0.542424:0.211470:0.915151:0.211470:0.915151:0.195714:0.542424:0.195714:0.014316:0.003848:0.007466:0.013143:0.013181:0.010660:0.013143:0.011738:0.006523:0.013143:0.012950:0.012508:0.007466:0.006111:0.012604:0.006042:0.006094:0.014239:0.014316:0.008197:0.006090:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.006098:0.011738:0.012604:0.006523:0.006088:0.004666:0.004666:0.011699:0.007466:0.011738:0.006388
es, libido loss and erectile dysfunction. Lat-:@0.524240:0.227941:0.915159:0.227941:0.915159:0.212185:0.524240:0.212185:0.012508:0.007466:0.005330:0.004657:0.003848:0.003848:0.013123:0.003848:0.013181:0.012615:0.004657:0.003848:0.012604:0.007466:0.007466:0.004657:0.013143:0.011738:0.013181:0.004657:0.012508:0.005711:0.012508:0.012450:0.006523:0.003848:0.003848:0.012508:0.004657:0.013181:0.010314:0.007466:0.006042:0.011699:0.011738:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.004639:0.008890:0.013143:0.006523:0.006388
er changes in weight, hair, muscle, bone, :@0.524240:0.244411:0.920499:0.244411:0.920499:0.228655:0.524240:0.228655:0.012508:0.005792:0.006947:0.012450:0.011738:0.013143:0.011738:0.012950:0.012508:0.007466:0.006947:0.003848:0.011738:0.006947:0.015990:0.012508:0.003848:0.012950:0.011738:0.006523:0.005330:0.006947:0.011738:0.013143:0.003848:0.003772:0.005330:0.006947:0.018049:0.011699:0.007466:0.012450:0.003848:0.012508:0.005330:0.006947:0.013123:0.012604:0.011738:0.012508:0.005330:0.005330
fat, testicular size, penile length and gy-:@0.524240:0.260881:0.915149:0.260881:0.915149:0.245125:0.524240:0.245125:0.006042:0.013143:0.006523:0.005330:0.009025:0.006523:0.012508:0.007466:0.006523:0.003848:0.012450:0.011699:0.003848:0.013143:0.005792:0.009025:0.007466:0.003848:0.008178:0.012508:0.005330:0.009025:0.013123:0.012508:0.011738:0.003848:0.003848:0.012508:0.009025:0.003848:0.012508:0.011738:0.012950:0.006523:0.011738:0.009025:0.013143:0.011738:0.013181:0.009025:0.012950:0.010314:0.006388
naecomastia have been observed. :@0.524240:0.277352:0.861270:0.277352:0.861270:0.261596:0.524240:0.261596:0.011738:0.013143:0.012508:0.012450:0.012604:0.018049:0.013143:0.007466:0.006523:0.003848:0.013143:0.005330:0.011738:0.013143:0.010660:0.012508:0.005330:0.013123:0.012508:0.012508:0.011738:0.005330:0.012604:0.013123:0.007466:0.012508:0.005792:0.010660:0.012508:0.013181:0.005330:0.005330
Anaemia, hyperlipidaemia and hyper-:@0.542424:0.293822:0.915149:0.293822:0.915149:0.278066:0.542424:0.278066:0.014432:0.011930:0.013335:0.012700:0.018242:0.004041:0.013335:0.005523:0.008274:0.011930:0.010506:0.013316:0.012700:0.005984:0.004041:0.004041:0.013316:0.004041:0.013373:0.013335:0.012700:0.018242:0.004041:0.013335:0.008274:0.013335:0.011930:0.013373:0.008274:0.011930:0.010506:0.013316:0.012700:0.005984:0.006388
glycaemia have also been recorded. :@0.524240:0.310292:0.920489:0.310292:0.920489:0.294536:0.524240:0.294536:0.013143:0.004041:0.010506:0.012642:0.013335:0.012700:0.018242:0.004041:0.013335:0.014239:0.011930:0.013335:0.010853:0.012700:0.014239:0.013335:0.004041:0.007658:0.012796:0.014239:0.013316:0.012700:0.012700:0.011930:0.014239:0.005904:0.012700:0.012642:0.012796:0.005867:0.013373:0.012700:0.013373:0.005326:0.005330
Fatigue, depression and emotion varia-:@0.524240:0.326763:0.915166:0.326763:0.915166:0.311007:0.524240:0.311007:0.009525:0.013335:0.006716:0.004041:0.013143:0.011892:0.012700:0.005523:0.010045:0.013373:0.012700:0.013316:0.005905:0.012700:0.007658:0.007658:0.004041:0.012796:0.011930:0.010045:0.013335:0.011930:0.013373:0.010045:0.012700:0.018242:0.012796:0.006716:0.004041:0.012796:0.011930:0.010045:0.010853:0.013335:0.005984:0.004041:0.013335:0.006388
tions may also occur. In castration-resist-:@0.524240:0.343233:0.915147:0.343233:0.915147:0.327477:0.524240:0.327477:0.006716:0.004041:0.012796:0.011930:0.007658:0.007703:0.018242:0.013335:0.010506:0.007703:0.013335:0.004041:0.007658:0.012796:0.007703:0.012796:0.012642:0.012642:0.011892:0.004570:0.005523:0.007703:0.004541:0.011930:0.007703:0.012642:0.013335:0.007658:0.006716:0.005984:0.013335:0.006716:0.004041:0.012796:0.011930:0.006581:0.005905:0.012700:0.007658:0.004041:0.007658:0.006716:0.006388
ant prostate cancer, ADT should not be :@0.524240:0.359703:0.920508:0.359703:0.920508:0.343947:0.524240:0.343947:0.013335:0.011930:0.006716:0.008467:0.013316:0.005904:0.012796:0.007658:0.006716:0.013335:0.006716:0.012700:0.008467:0.012642:0.013335:0.011930:0.012642:0.012700:0.003960:0.005523:0.008467:0.014432:0.014509:0.008390:0.008467:0.007658:0.011930:0.012796:0.011892:0.004041:0.013373:0.008467:0.011930:0.012796:0.006716:0.008467:0.013316:0.012506:0.005330
stopped as some prostate-cancer cells :@0.524240:0.376174:0.920481:0.376174:0.920481:0.360418:0.524240:0.360418:0.007658:0.006716:0.012796:0.013316:0.013316:0.012700:0.013373:0.010699:0.013335:0.007658:0.010699:0.007658:0.012796:0.018242:0.012700:0.010699:0.013316:0.005905:0.012796:0.007658:0.006716:0.013335:0.006716:0.012700:0.006581:0.012642:0.013335:0.011930:0.012642:0.012700:0.005984:0.010699:0.012642:0.012700:0.004041:0.004041:0.007470:0.005330
remain sensitive.:@0.524240:0.392644:0.679543:0.392644:0.679543:0.376888:0.524240:0.376888:0.005905:0.012700:0.018242:0.013335:0.004041:0.011930:0.005523:0.007658:0.012700:0.011930:0.007658:0.004041:0.006716:0.004041:0.010853:0.012700:0.005330
Abiraterone acetate (Zytiga):@0.542424:0.409114:0.813222:0.409114:0.813222:0.393080:0.542424:0.393080:0.014239:0.012700:0.004618:0.006158:0.012700:0.005773:0.012315:0.006158:0.012315:0.011545:0.012315:0.007428:0.012700:0.012315:0.012315:0.005773:0.012700:0.005773:0.012315:0.007447:0.007312:0.009621:0.011161:0.005773:0.004618:0.012700:0.012700:0.007312
 :@0.653260:0.409114:0.658590:0.409114:0.658590:0.393358:0.653260:0.393358:0.005330
 :@0.734578:0.409114:0.739909:0.409114:0.739909:0.393358:0.734578:0.393358:0.005330
 is a selec-:@0.813222:0.409114:0.915165:0.409114:0.915165:0.393358:0.813222:0.393358:0.007433:0.003848:0.007466:0.007447:0.013143:0.007437:0.007466:0.012508:0.003848:0.012508:0.012450:0.006388
tive inhibitor of CYP 17, a key enzyme along :@0.524240:0.425584:0.920489:0.425584:0.920489:0.409829:0.524240:0.409829:0.006523:0.003848:0.010660:0.012508:0.003425:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.003425:0.012604:0.006042:0.003425:0.015644:0.011392:0.011392:0.003425:0.010660:0.010660:0.005330:0.003425:0.013143:0.003425:0.009660:0.012508:0.010314:0.003425:0.012508:0.011738:0.008178:0.010314:0.018049:0.012508:0.003416:0.013143:0.003848:0.012604:0.011738:0.012950:0.005330
the biosynthesis of androgens – both in the :@0.524240:0.442055:0.920497:0.442055:0.920497:0.426299:0.524240:0.426299:0.006523:0.011738:0.012508:0.004545:0.013123:0.003848:0.012604:0.007466:0.010314:0.011738:0.006523:0.011738:0.012508:0.007466:0.003848:0.007466:0.004560:0.012604:0.006042:0.004549:0.013143:0.011738:0.013181:0.005713:0.012604:0.012950:0.012508:0.011738:0.007466:0.004545:0.009621:0.004560:0.013123:0.012604:0.006523:0.011738:0.004545:0.003848:0.011738:0.004560:0.006523:0.011738:0.012508:0.005330
adrenal glands and in tumour cells. It has :@0.524240:0.458525:0.920447:0.458525:0.920447:0.442769:0.524240:0.442769:0.013143:0.013181:0.005715:0.012508:0.011738:0.013143:0.003848:0.006658:0.012950:0.003848:0.013143:0.011738:0.013181:0.007466:0.006658:0.013143:0.011738:0.013181:0.006658:0.003848:0.011738:0.006658:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.006644:0.012450:0.012508:0.003848:0.003848:0.007466:0.005330:0.006658:0.004349:0.006523:0.006658:0.011738:0.013143:0.007466:0.005330
demonstrated significant  anti-tumour ac-:@0.524240:0.474995:0.915151:0.474995:0.915151:0.459239:0.524240:0.459239:0.013181:0.012508:0.018049:0.012604:0.011738:0.007466:0.006523:0.005792:0.013143:0.006523:0.012508:0.013181:0.008205:0.007466:0.003848:0.012950:0.011738:0.003848:0.004686:0.004686:0.012450:0.013143:0.011738:0.006523:0.005330:0.002888:0.013143:0.011738:0.006523:0.003848:0.006388:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.008209:0.013143:0.012450:0.006388
tivity (PSA  declines by 50% in  50-60% of :@0.524240:0.491466:0.920495:0.491466:0.920495:0.475710:0.524240:0.475710:0.006523:0.003848:0.010660:0.003848:0.006523:0.010314:0.010218:0.007100:0.011392:0.009583:0.014239:0.005330:0.004874:0.013181:0.012508:0.012450:0.003848:0.003848:0.011738:0.012508:0.007466:0.010218:0.013123:0.010314:0.010218:0.010660:0.010660:0.014913:0.010218:0.003848:0.011738:0.005330:0.004878:0.010660:0.010660:0.006388:0.010660:0.010660:0.014913:0.010218:0.012604:0.006042:0.005330
both chemo-naive and chemo-refractory :@0.524240:0.507936:0.920502:0.507936:0.920502:0.492180:0.524240:0.492180:0.013123:0.012604:0.006523:0.011738:0.006215:0.012450:0.011738:0.012508:0.018049:0.012604:0.006388:0.011738:0.013133:0.003848:0.010660:0.012508:0.006215:0.013143:0.011738:0.013181:0.006215:0.012450:0.011738:0.012508:0.018049:0.012604:0.006388:0.005709:0.012508:0.006042:0.005792:0.013143:0.012450:0.006523:0.012604:0.005792:0.010314:0.005330
metastatic castration-resistant  prostate :@0.524240:0.524406:0.920481:0.524406:0.920481:0.508650:0.524240:0.508650:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.019300:0.012450:0.013143:0.007466:0.006523:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.006388:0.005707:0.012508:0.007466:0.003848:0.007466:0.006523:0.013143:0.011738:0.006523:0.005330:0.013958:0.013123:0.005717:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.005330
cancer). It  has  demonstrated  improved :@0.524240:0.540877:0.920484:0.540913:0.920484:0.525157:0.524240:0.525121:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.007100:0.005330:0.007201:0.004349:0.006523:0.005330:0.007031:0.011738:0.013143:0.007466:0.005330:0.007031:0.013181:0.012508:0.018049:0.012604:0.011738:0.007466:0.006523:0.005792:0.013143:0.006523:0.012498:0.013181:0.005330:0.007033:0.003848:0.018049:0.013123:0.005719:0.012604:0.010660:0.012508:0.013181:-0.224473
 :@0.604744:0.535294:0.607852:0.535294:0.607852:0.526108:0.604744:0.526108:0.003107
OS (14.8:@0.524244:0.557383:0.599886:0.557383:0.599886:0.541627:0.524244:0.541627:0.016722:0.009583:0.004926:0.007100:0.010660:0.010660:0.005330:0.010660
 vs :@0.599886:0.557383:0.628269:0.557383:0.628269:0.541627:0.599886:0.541627:0.004926:0.010660:0.007466:0.005330
10.9m, HR 0.65, 95%CI0.54-0.77) :@0.627864:0.557383:0.920472:0.557383:0.920472:0.541627:0.627864:0.541627:0.010660:0.010660:0.005330:0.010660:0.018049:0.005330:0.004915:0.013143:0.011680:0.004926:0.010660:0.005330:0.010660:0.010660:0.005330:0.004926:0.010660:0.010660:0.014913:0.015644:0.004349:0.010660:0.005330:0.010660:0.010660:0.006388:0.010660:0.005330:0.010660:0.010680:0.007100:0.005330
in the post-docetaxel setting   and in the :@0.524244:0.573853:0.920470:0.573857:0.920470:0.558101:0.524244:0.558097:0.003848:0.011738:0.007177:0.006523:0.011738:0.012508:0.007177:0.013123:0.012604:0.007466:0.006523:0.006388:0.013181:0.012604:0.012450:0.012508:0.006523:0.013143:0.009236:0.012508:0.003848:0.007177:0.007466:0.012508:0.006523:0.006523:0.003848:0.011738:0.012950:0.005330:0.008068:0.007177:0.013143:0.011738:0.013181:0.007177:0.003848:0.011738:0.007177:0.006523:0.011738:0.012508:-0.272378
6:@0.802974:0.568238:0.809189:0.568238:0.809189:0.559052:0.802974:0.559052:0.006215
pre-chemo setting   (although not statisti-:@0.524249:0.590327:0.915144:0.590329:0.915144:0.574573:0.524249:0.574571:0.013123:0.005715:0.012508:0.006388:0.012450:0.011738:0.012508:0.018049:0.012604:0.006818:0.007466:0.012508:0.006523:0.006523:0.003848:0.011738:0.012950:0.005330:0.007701:0.006831:0.007100:0.013143:0.003848:0.006523:0.011738:0.012604:0.011699:0.012950:0.011738:0.006820:0.011738:0.012604:0.006523:0.006818:0.007466:0.006523:0.013143:0.006523:0.003848:0.007466:0.006523:0.003848:-0.289953
7:@0.704520:0.584710:0.710735:0.584710:0.710735:0.575525:0.704520:0.575525:0.006215
cally significant).:@0.524240:0.606799:0.678680:0.606799:0.678680:0.591044:0.524240:0.591044:0.012450:0.013143:0.003848:0.003848:0.010314:0.005330:0.007466:0.003848:0.012950:0.011738:0.003848:0.004686:0.004686:0.012450:0.013143:0.011738:0.006523:0.007100:0.005330
Abiraterone is  generally well  tolerated, :@0.542424:0.623270:0.920495:0.623270:0.920495:0.607514:0.542424:0.607514:0.014239:0.013123:0.003848:0.005792:0.013143:0.006523:0.012508:0.005707:0.012604:0.011738:0.012508:0.008717:0.003848:0.007466:0.005330:0.003398:0.012950:0.012508:0.011738:0.012508:0.005792:0.013143:0.003848:0.003848:0.010314:0.008717:0.015990:0.012508:0.003848:0.003848:0.005330:0.003398:0.006523:0.012604:0.003848:0.012508:0.005792:0.013143:0.006523:0.012508:0.013181:0.005330:0.005330
but does cause some fluid retention, and :@0.524240:0.639740:0.920484:0.639740:0.920484:0.623984:0.524240:0.623984:0.013123:0.011699:0.006523:0.006794:0.013181:0.012604:0.012508:0.007466:0.006800:0.012450:0.013143:0.011699:0.007466:0.012508:0.006796:0.007466:0.012604:0.018049:0.012508:0.006793:0.004666:0.004666:0.011699:0.003848:0.013181:0.006798:0.005711:0.012508:0.006523:0.012508:0.011738:0.006523:0.003848:0.012604:0.011738:0.005330:0.006781:0.013143:0.011738:0.013181:0.005330
hypokalaemia in rare cases. If hyperten-:@0.524240:0.656210:0.915150:0.656210:0.915150:0.640454:0.524240:0.640454:0.011738:0.010314:0.013123:0.012604:0.009660:0.013143:0.003848:0.013143:0.012508:0.018049:0.003848:0.013143:0.008736:0.003848:0.011738:0.008736:0.005792:0.013143:0.005711:0.012508:0.008736:0.012450:0.013143:0.007466:0.012508:0.007466:0.005330:0.008736:0.004349:0.006042:0.008736:0.011738:0.010314:0.013123:0.012508:0.005792:0.006523:0.012508:0.011722:0.006388
sion develops, it should be treated, but the :@0.524240:0.672681:0.920493:0.672681:0.920493:0.656925:0.524240:0.656925:0.007466:0.003848:0.012604:0.011738:0.004280:0.013181:0.012508:0.010660:0.012508:0.003848:0.012604:0.013123:0.007466:0.005330:0.004291:0.003848:0.006523:0.004280:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.004280:0.013123:0.012508:0.004280:0.006523:0.005711:0.012508:0.013143:0.006523:0.012508:0.013181:0.005330:0.004274:0.013123:0.011699:0.006523:0.004276:0.006523:0.011738:0.012508:0.005330
drug must be continued as long as there is :@0.524240:0.689151:0.920453:0.689151:0.920453:0.673395:0.524240:0.673395:0.013181:0.005792:0.011699:0.012950:0.004868:0.018049:0.011699:0.007466:0.006523:0.004868:0.013123:0.012508:0.004868:0.012450:0.012604:0.011738:0.006523:0.003848:0.011738:0.011699:0.012508:0.013181:0.004868:0.013143:0.007466:0.004868:0.003848:0.012604:0.011738:0.012950:0.004868:0.013143:0.007466:0.004868:0.006523:0.011738:0.012508:0.005707:0.012508:0.004868:0.003848:0.007466:0.005330
a clinical benefit.:@0.524240:0.705621:0.684318:0.705621:0.684318:0.689865:0.524240:0.689865:0.013143:0.005330:0.012450:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.005330:0.013123:0.012508:0.011738:0.012508:0.004686:0.004686:0.006523:0.005330
Enzalutamide (Xtandi):@0.542424:0.722092:0.749723:0.722092:0.749723:0.706058:0.542424:0.706058:0.010006:0.011545:0.008852:0.012700:0.004618:0.011545:0.005773:0.012700:0.018088:0.004618:0.012700:0.012315:0.006793:0.007312:0.013085:0.005773:0.012700:0.011545:0.012700:0.004618:0.007312
 is a novel andro-:@0.749723:0.722092:0.915167:0.722092:0.915167:0.706336:0.749723:0.706336:0.006716:0.003848:0.007466:0.006716:0.013143:0.006716:0.011738:0.012604:0.010660:0.012508:0.003848:0.006716:0.013143:0.011738:0.013181:0.005713:0.012604:0.006388
gen receptor signal inhibitor. It has shown :@0.524240:0.738562:0.920539:0.738562:0.920539:0.722806:0.524240:0.722806:0.012758:0.012315:0.011545:0.007793:0.005519:0.012315:0.012257:0.012315:0.012931:0.006331:0.012411:0.005600:0.007793:0.007274:0.003656:0.012758:0.011545:0.012950:0.003656:0.007793:0.003656:0.011545:0.011545:0.003656:0.012931:0.003656:0.006331:0.012411:0.004185:0.005138:0.007793:0.004156:0.006331:0.007793:0.011545:0.012950:0.007274:0.007793:0.007274:0.011545:0.012411:0.015798:0.011734:0.005330
an overall survival benefit:@0.524240:0.755032:0.754052:0.755032:0.754052:0.739276:0.524240:0.739276:0.012950:0.011545:0.004624:0.012411:0.010468:0.012315:0.005600:0.012950:0.003656:0.003656:0.004624:0.007274:0.011507:0.005600:0.010468:0.003656:0.010468:0.012950:0.003656:0.004626:0.012931:0.012315:0.011545:0.012315:0.004589:0.004589:0.006523
 vs :@0.753860:0.755032:0.781555:0.755032:0.781555:0.739276:0.753860:0.739276:0.004624:0.010468:0.007274:0.005330
placebo in the :@0.780857:0.755032:0.920470:0.755032:0.920470:0.739276:0.780857:0.739276:0.012931:0.003656:0.012950:0.012257:0.012315:0.012931:0.012411:0.004624:0.003656:0.011545:0.004624:0.006331:0.011545:0.012506:0.005330
AFFIRM trial in patients’ post progression :@0.524240:0.771503:0.920489:0.771503:0.920489:0.755747:0.524240:0.755747:0.014047:0.009140:0.009140:0.004156:0.011488:0.017491:0.011084:0.006331:0.005600:0.003656:0.012950:0.003656:0.011084:0.003656:0.011545:0.011084:0.012931:0.012950:0.006331:0.003656:0.012315:0.011545:0.006331:0.007274:0.006562:0.011084:0.012931:0.012411:0.007274:0.006331:0.011084:0.012931:0.005519:0.012411:0.012758:0.005521:0.012315:0.007274:0.007274:0.003656:0.012411:0.011734:0.005330
on docetaxel.  Median survival was 18.4:@0.524240:0.787973:0.891646:0.787995:0.891646:0.772239:0.524240:0.772217:0.012411:0.011545:0.005734:0.012989:0.012411:0.012257:0.012315:0.006331:0.012950:0.009044:0.012315:0.003656:0.005330:0.005898:0.005734:0.017491:0.012315:0.012989:0.003656:0.012950:0.011545:0.005734:0.007274:0.011507:0.005600:0.010468:0.003656:0.010468:0.012950:0.003656:0.005734:0.015798:0.012950:0.007274:0.005734:0.010468:0.010468:0.005138:-0.549697
8:@0.653323:0.782376:0.659538:0.782376:0.659538:0.773190:0.653323:0.773190:0.006215
 vs :@0.891453:0.787995:0.920453:0.787995:0.920453:0.772239:0.891453:0.772239:0.005734:0.010468:0.007468:0.005330
13.6 months with HR 0.63;95% CI, 0.53-0.75). :@0.524250:0.804465:0.920430:0.804465:0.920430:0.788709:0.524250:0.788709:0.010468:0.010468:0.005138:0.010468:0.005330:0.017857:0.012411:0.011545:0.006331:0.011545:0.007274:0.005330:0.015798:0.003656:0.006331:0.011545:0.005330:0.012950:0.011488:0.005330:0.010468:0.005138:0.010468:0.010468:0.005138:0.010468:0.010468:0.014720:0.005330:0.015452:0.004156:0.005138:0.005330:0.010468:0.005138:0.010468:0.010468:0.006196:0.010468:0.005138:0.010468:0.010468:0.006908:0.005328:0.005330
It was superior in all secondary parameters, :@0.524250:0.820935:0.920507:0.820935:0.920507:0.805179:0.524250:0.805179:0.004156:0.006331:0.004791:0.015798:0.012950:0.007274:0.004791:0.007274:0.011507:0.012931:0.012315:0.005600:0.003656:0.012411:0.005600:0.004791:0.003656:0.011545:0.004791:0.012950:0.003656:0.003656:0.004791:0.007274:0.012315:0.012257:0.012411:0.011545:0.012989:0.012950:0.005600:0.010122:0.004791:0.012931:0.012950:0.005600:0.012950:0.017857:0.012315:0.006331:0.012315:0.005600:0.007274:0.005328:0.005330
namely PSA reduction, time to progression, :@0.524250:0.837406:0.920538:0.837406:0.920538:0.821650:0.524250:0.821650:0.011545:0.012950:0.017857:0.012315:0.003656:0.010122:0.005272:0.011199:0.009390:0.014047:0.005272:0.005521:0.012315:0.012989:0.011507:0.012257:0.006331:0.003656:0.012411:0.011545:0.005138:0.005272:0.006331:0.003656:0.017857:0.012315:0.005272:0.006331:0.012411:0.005272:0.012931:0.005521:0.012411:0.012758:0.005521:0.012315:0.007274:0.007274:0.003656:0.012411:0.011545:0.005326:0.005330
radiological  progression-free survival  and :@0.524250:0.853876:0.920482:0.853876:0.920482:0.838120:0.524250:0.838120:0.005600:0.012950:0.012989:0.003656:0.012411:0.003656:0.012411:0.012758:0.003656:0.012257:0.012950:0.003656:0.005330:0.005628:0.012931:0.005521:0.012411:0.012758:0.005521:0.012315:0.007274:0.007274:0.003656:0.012411:0.011545:0.006196:0.005850:0.005519:0.012315:0.012315:0.010968:0.007274:0.011507:0.005600:0.010468:0.003656:0.010468:0.012950:0.003656:0.005330:0.005628:0.012950:0.011545:0.013181:0.005330
time to first skeletal-related event.:@0.524250:0.870346:0.830626:0.870346:0.830626:0.854590:0.524250:0.854590:0.006331:0.003656:0.017857:0.012315:0.005138:0.006331:0.012411:0.005138:0.004589:0.004589:0.005600:0.007274:0.006331:0.005138:0.007274:0.009467:0.012315:0.003656:0.012315:0.006331:0.012950:0.003656:0.006196:0.005521:0.012315:0.003656:0.012950:0.006331:0.012315:0.012989:0.005138:0.012315:0.010468:0.012315:0.011545:0.006331:0.005330
Enzalutamide is well tolerated, with later :@0.542434:0.886817:0.920501:0.886817:0.920501:0.871061:0.542434:0.871061:0.010314:0.011738:0.008178:0.013143:0.003848:0.011699:0.006523:0.013143:0.018049:0.003848:0.013181:0.012508:0.005446:0.003848:0.007466:0.005436:0.015990:0.012508:0.003848:0.003848:0.005446:0.006523:0.012604:0.003848:0.012508:0.005792:0.013143:0.006523:0.012508:0.013181:0.005330:0.005421:0.015990:0.003848:0.006523:0.011738:0.005434:0.003848:0.013143:0.006523:0.012508:0.005792:0.005330
onset of fatigue, mild diarrhoea and hot :@0.524250:0.903287:0.920536:0.903287:0.920536:0.887531:0.524250:0.887531:0.012604:0.011738:0.007466:0.012508:0.006523:0.008201:0.012604:0.006042:0.008217:0.006042:0.013143:0.006523:0.003848:0.012950:0.011699:0.012508:0.005330:0.008205:0.018049:0.003848:0.003848:0.013181:0.008217:0.013181:0.003848:0.013143:0.005792:0.006346:0.011738:0.012604:0.012508:0.013143:0.008217:0.013143:0.011738:0.013181:0.008217:0.011738:0.012604:0.006523:0.005330
flushes. It does not require the use of con-:@0.524250:0.919757:0.915166:0.919757:0.915166:0.904001:0.524250:0.904001:0.004666:0.004666:0.011699:0.007466:0.011738:0.012508:0.007466:0.005330:0.006061:0.004349:0.006523:0.006065:0.013181:0.012604:0.012508:0.007466:0.006065:0.011738:0.012604:0.006523:0.006056:0.005713:0.012508:0.013123:0.011699:0.003848:0.005715:0.012508:0.006065:0.006523:0.011738:0.012508:0.006059:0.011699:0.007466:0.012508:0.006065:0.012604:0.006042:0.006061:0.012450:0.012604:0.011738:0.006388
comitant steroids.:@0.524250:0.936227:0.689087:0.936227:0.689087:0.920472:0.524250:0.920472:0.012450:0.012604:0.018049:0.003848:0.006523:0.013143:0.011738:0.006523:0.005330:0.007466:0.006523:0.012508:0.005702:0.012604:0.003848:0.013181:0.007466:0.005330